Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Athenex, Inc. (NASDAQ: ATNX).

Full DD Report for ATNX

You must become a subscriber to view this report.


Recent News from (NASDAQ: ATNX)

Athenex's (ATNX) CEO, Johnson Lau on Q1 2018 Results - Earnings Call Transcript
Athenex Inc. (ATNX) Q1 2018 Earnings Conference Call May 14, 2018 9:00 am ET Executives Johnson Lau - Chief Executive Officer Jeffrey Yordon - President, Chief Operating Officer Rudolph Kwan - Chief Medical Officer Li Shen - Chief Accounting Officer (acting) Jim Polson - Inve...
Source: SeekingAlpha
Date: May, 14 2018 14:42
Athenex's KX2-391 completes patient enrollment for both Phase III clinical studies months ahead of schedule
Athenex ( ATNX -0.5% ) reports Q1 revenue growth of 726% Y/Y to $37.8M; the increase was due to $25M in upfront license fees related to the collaboration agreement with Almirall, S.A; $8.6M specialty products sold through commercial platform & $0.4M sales of 503B products. Mor...
Source: SeekingAlpha
Date: May, 14 2018 10:43
Athenex reports Q1 results
Athenex (NASDAQ: ATNX ): Q1 net loss of $7.3M More news on: Athenex, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 14 2018 07:02
Athenex, Inc. Announces First Quarter 2018 Results
Significant Clinical Milestones and Record Revenue Mark Strong Start to Fiscal 2018 First Quarter 2018 and Recent Business Highlights: Received Orphan Drug Designation from the FDA for Oraxol for the treatment of angiosarcoma Generated revenue of $37.8 million for the first qua...
Source: GlobeNewswire
Date: May, 14 2018 07:00
Athenex to Present at Deutsche Bank's 43rd Annual Health Care Conference
BUFFALO, N.Y., May 08, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will present a...
Source: GlobeNewswire
Date: May, 08 2018 08:00
Athenex, Inc. to Report First Quarter Earnings Results on May 14, 2018
BUFFALO, N.Y., May 03, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, will release first quarter 2018 earnings resul...
Source: GlobeNewswire
Date: May, 03 2018 08:00
Athenex, Inc. Announces Transition of James Zukin from Board of Directors to Advisory Role
BUFFALO, N.Y., April 30, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the transition of James Zuki...
Source: GlobeNewswire
Date: April, 30 2018 06:30
Blog Exposure - FDA Granted Fast Track Designation to Calithera Biosciences' CB-839 in Combination with Cabozantinib for Advanced Renal Cell Carcinoma Treatment
Stock Monitor: Athenex Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Calithera Biosciences, Inc. (NASDAQ: CALA ) ("Calithera"). If you want access to this report all you need to do is sign up now by...
Source: ACCESSWIRE IA
Date: April, 20 2018 07:40
Athenex, Inc. Receives U.S. FDA Orphan Drug Designation for Oraxol for the Treatment of Angiosarcoma
BUFFALO, N.Y., April 19, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has received Orphan ...
Source: GlobeNewswire
Date: April, 19 2018 08:00
Report: Exploring Fundamental Drivers Behind Exponent, Monotype Imaging, Athenex, State Street, Heartland Financial, and IRSA Inversiones Y Representaciones S.A - New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, April 18, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Exponent, Inc. (NASDAQ:EXPO), Monotype Imaging Holdings Inc. (NASDAQ:TYP...
Source: GlobeNewswire
Date: April, 18 2018 08:10

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1716.8817.0017.0416.71149,626

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1648,37472,42566.7919Short
2018-08-1540,34072,56155.5946Short
2018-08-1448,692116,50041.7957Short
2018-08-1328,08846,44860.4719Short
2018-08-1014,65881,83217.9123Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ATNX.


About Athenex, Inc. (NASDAQ: ATNX)

Logo for Athenex, Inc. (NASDAQ: ATNX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ATNX)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 14 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 14 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: May, 14 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: May, 07 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 30 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 30 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 30 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: April, 27 2018
      Filing by person(s) reporting owned shares of common stock in a public company >5%
      Filing Type: SC 13DFiling Source: edgar
      Filing Date: April, 27 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: April, 27 2018

       

       


      Daily Technical Chart for (NASDAQ: ATNX)

      Daily Technical Chart for (NASDAQ: ATNX)


      Stay tuned for daily updates and more on (NASDAQ: ATNX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ATNX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATNX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ATNX and does not buy, sell, or trade any shares of ATNX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/